DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the Read more »
HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) — Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday's decision by the U.S. Food and Drug [...] Read more »